The Buckland Group launched Quvara Medical as the newest CDMO to debut this year after buying a former Becton Dickinson manufacturing site in the U.K. for an undisclosed price.
Quvara joins the ranks of at least five CDMOs that launched in 2025, including Rezon Bio, Codis, Meribel and Artis BioSolutions.
The company, which will operate out of the former Becton facility in Swindon, England, focuses on high-precision, high-volume production for the medical device and pharmaceutical industries, the company said in a Dec. 2 press release.
Although financial terms of the acquisition were not disclosed, the company said the “facility remains operational with full workforce retention.”
The former Becton site, which has been in operation for two decades, specializes in manufacturing prefilled syringes.
“This acquisition is part of our strategy to build specialised, sector-leading businesses under the Quvara Group banner,” Paul Bragg, Buckland’s managing director, said in a statement. “Medical manufacturing is the first—but not the last area where we’re applying this model.”
“We offer clients the speed, agility, and compliance they demand, built on decades of manufacturing excellence,” Neil Sibley, chief executive of Quvara Medical, said.
Quvara’s announcement comes almost two months after Codis launched in the wake of a deal that combined U.S.-based Particle Dynamics with a U.K. spray drying plant previously operated by EuroAPI.
In September, biologics-focused Rezon Bio debuted with two manufacturing sites in Poland. Meribel rolled out in April after a financial backer bought a string of production sites from Recipharm and the purchase of France’s Synerlab. The same month, cell and gene therapy CDMO Artis BioSolutions also launched.